Traders should monitor the March 2026 data readouts closely, as clinical updates could drive volatility. The cash runway appears sufficient for near-term operations, but the 46% decline in cash over one year raises longer-term funding questions if milestones are delayed.
Price Chart
Executive Summary
OnKure Therapeutics reported Q4 and full-year 2025 financial results, showing reduced R&D and G&A expenses leading to a narrower net loss of $13.5M (-22% YoY improvement). The company highlighted upcoming clinical data readouts for OKI-219 in March 2026 and plans to announce a next-generation PI3Kα pan-mutant inhibitor. Cash balance stood at $59.1M as of year-end, down from $110.8M in 2024.
Key Financial Metrics
Key Facts
- Q4 2025 net loss was $13.5M vs. $17.4M in Q4 2024, with EPS improving from -$1.37 to -$0.99
- R&D expenses decreased to $10.7M from $14.4M YoY due to lower clinical and personnel costs
- Cash and cash equivalents declined to $59.1M as of December 31, 2025, from $110.8M in 2024
- Updated clinical data from PIKture-01 trial expected in March 2026 for multiple arms
- Next-generation PI3Kα pan-mutant inhibitor candidate to be announced in March 2026
Financial Impact
Reduced quarterly loss by $3.9M; full-year loss of $59.5M vs. $52.7M in 2024, despite higher annual R&D spend
Risk Factors
- Cash burn remains high; cash balance dropped 46% from 2024 to 2025
- Forward-looking statements dominate; no revenue-generating products or near-term commercial catalysts
- Clinical trial outcomes are uncertain and may not meet expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255093 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 18d ago | SC 13G | $2.30 | awaiting T+60 | — | $2.47 (+7.61%) |
Aug 4, 2026 11w ago | 8-K | $4.16 | awaiting T+60 | — | $2.47 (−40.50%) |
Apr 24, 2026 26w ago | S-3 | $4.99 $4.32 | ▲ +13.43% | ▲ +18.20% | $2.47 (+50.40%) |
Apr 21, 2026 26w ago | DEFA14A | $5.01 $4.20 | ▼ −16.17% | ▼ −20.95% | $2.47 (−50.60%) |
Mar 23, 2026 31w ago | Insider Cluster | $3.98 $4.29 | ▲ +7.79% | ▼ −5.27% | $2.47 (−37.81%) |
Mar 12, 2026 32w ago | Press Release | $3.78 $4.40 | ▲ +16.40% | ▲ +4.79% | $2.47 (−34.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers